Search results for "Osteon"

showing 10 items of 236 documents

Osteonecrosis of the jaw related to everolimus and bisphosphonate: a unique case report?

2013

Osteonecrosis of the jaw (ONJ) is a rare but serious lesion of the jaw, characterized mainly by exposed necrotic bone;it is related to various drugs, usually used for treating patients with advanced malignancies. Drugs implicated in ONJ are: nitrogen-containing bisphosphonates (NBPs), denosumab, anti-angiogenic drugs (e.g bevacizumab, sunitinib,sorafenib) and the selective mammalian target of rapamycin mTOR, everolimus. Previous data regarding the combining of NBPs with antiangiogenic agents conflict with some reports (indicating a similar risk of ONJ compared with the use of NBPs alone1); other reports show significantly higher rates (18% vs 1% with NBPs alone) of the incidence of ONJ2. Th…

Settore MED/28 - Malattie OdontostomatologicheCase Reportosteonecrosis of the jaws everolimus
researchProduct

OSTEONECROSIS OF THE JAW: AN UNUSUAL CASE REPORT

2008

Settore MED/28 - Malattie OdontostomatologicheOSTEONECROSIS OF THE JAW
researchProduct

Management of osteonecrosis of the jaws

2010

Settore MED/28 - Malattie OdontostomatologicheOsteonecrosis jaws
researchProduct

Prevenzione e management odontoiatrico dei pazienti oncologici a rischio di osteonecrosi delle ossa mascellari da farmaci.

2016

non disponibile

Settore MED/28 - Malattie OdontostomatologichePrevenzione management odontoiatrico pazienti oncologici osteonecrosi delle ossa mascellari da farmaci bisfosfonati
researchProduct

Osteonecrosi dei mascellari associata a bisfosfonati,denosumab e farmaci anti-angiogenetici nei pazienti oncologici e osteoporotici: prevenzione dent…

2013

Obiettivi. Proporre protocolli di gestione odontoiatrica per il paziente che assume o che assumerà farmaci (per esempio bisfosfonati, denosumab e anti-angiogenetici) correlati all’insorgenza di osteonecrosi dei mascellari (OsteoNecrosis of the Jaws, ONJ). Materiali e metodi. Gli autori del lavoro, recentemente estensori e collaboratori – su mandato della Società Italiana di Chirurgia Maxillo-Facciale (SICMF) e della Società Italiana di Patologia e Medicina Orale (SIPMO), delle Raccomandazioni clinicoterapeutiche sull’osteonecrosi delle ossa mascellari associata a bisfosfonati e sua prevenzione – hanno esaminato le informazioni in rapporto con le procedure odontoiatriche. Risultati e conclus…

Settore MED/28 - Malattie OdontostomatologicheSettore MED/50 - Scienze Tecniche Mediche Applicateosteonecrosi dei mascellari prevenzione
researchProduct

Surgical treatment of medication-related osteonecrosis of the jaws with addiction of L-PRF: preliminary results

2018

Surgical treatment medication-related osteonecrosis of the jaws L-PRF
researchProduct

Osteonecrosis of jaw beyond antiresorptive (bone-targeted) agents: new horizons in oncology

2016

Introduction: Osteonecrosis of the jaw (ONJ) is a clinically important, potentially painful and debilitating condition, which can affect the quality of life of cancer patients. Since 2003, ONJ appeared as a Bisphosphonate(BP)-related class effect, and the term Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ) was widespread. Areas Covered: Under discussion in this review is the fact that ONJ cases have been reported after treatment including antiangiogenic agents and other “targeted therapy”, with and without BPs. Consequently, the comprehensive term Medication-Related Osteonecrosis of the Jaw (MRONJ) has been introduced. The clinical aspects and the prognosis of ONJ associated with t…

aflibercept; bevacizumab; Bisphosphonate; Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ); denosumab; everolimus; Medication-Related Osteonecrosis of the Jaw (MRONJ); Osteonecrosis of the jaw (ONJ); sunitinib; temsirolimus; Angiogenesis Inhibitors; Antineoplastic Agents; Bisphosphonate-Associated Osteonecrosis of the Jaw; Humans; Jaw Diseases; Molecular Targeted Therapy; Neoplasms; Osteonecrosis; Quality of Life; Risk Assessment; Pharmacology (medical)Oncologysunitinibmedicine.medical_treatmentAngiogenesis InhibitorstemsirolimuTargeted therapyAntineoplastic Agent0302 clinical medicineNeoplasmsPharmacology (medical)Molecular Targeted TherapyJaw DiseaseafliberceptOsteonecrosisGeneral MedicineDenosumab030220 oncology & carcinogenesisOsteonecrosiBisphosphonate-Associated Osteonecrosis of the JawAngiogenesis InhibitorHumanmedicine.drugmedicine.medical_specialtyBevacizumabAntineoplastic AgentsbevacizumabRisk AssessmentBisphosphonate-Related Osteonecrosis of the Jaw (BRONJ)Medication-Related Osteonecrosis of the Jaw (MRONJ)03 medical and health sciencesInternal medicinemedicineBisphosphonateHumansBisphosphonate-associated osteonecrosis of the jawbusiness.industryeverolimuCancerdenosumab030206 dentistryBisphosphonatemedicine.diseaseOsteonecrosis of the jaw (ONJ)Quality of LifeNeoplasmJaw DiseasesOsteonecrosis of the jawbusinessJaw DiseasesExpert Opinion on Drug Safety
researchProduct

Findings of osteonecrosis of the jaw under combined bisphosphonate and antiangiogenic therapies: an emergent problem?

2011

antiangiogenic agentsSettore MED/09 - Medicina InternaOsteonecrosis of the jawSettore MED/28 - Malattie OdontostomatologicheSettore BIO/14 - Farmacologiabisphosponate
researchProduct

Bisfosfonati: utilità terapeutiche e reazioni avverse di interesse odontostomatologico

2020

I bifosfonati hanno la capacità di modulare il turnover osseo, controllare e ridurre il rimodellamento in corso di riassorbimento.Il loro meccanismo d’azione si basa sulla capacità di inibire il riassorbimento osseo mediato dagli osteoclasti.

bisfosfonati osteonecrosi ossa mascellari da farmaci reazione avversa
researchProduct

Significance of immunohistochemistry biomarkers in prediction of malignant transformation of oral lichen planus

2022

Background: Oral lichen planus (OLP) is a chronic inflammatory disorder with increased risk for malignant transformation. Biomarker validation is a pivotal step in moving newly discovered biomarkers towards clinical implementation. We performed a systematic review of studies on biomarkers related to OLP, wherein biomarkers have been described in at least two independent studies. Our aim was to determine whether any of these biomark-ers might be promising in predicting the increased risk of malignant transformation of OLP. Material and Methods: We searched the following databases until August 2021: PUBMED, EMBASE, and Web of Science. Due to high heterogeneity, a qualitative rather than quant…

bisphosphonate osteonecrosisp53malignant transformationP21bone densitybiomarkerscomputed tomographycervical vertebraeImmunohistochemistryCell Transformation NeoplasticjawOtorhinolaryngologySDG 3 - Good Health and Well-beingProliferating Cell Nuclear AntigenOral lichen planusBCl-2Humans/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingPCNAMouth NeoplasmsSurgeryGeneral DentistryUNESCO:CIENCIAS MÉDICASLichen Planus OralMedicina oral patologia oral y cirugia bucal
researchProduct